a  
Bortezomib SUN 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0019/G 
This was an application for a group of variations. 
31/08/2021 
SmPC 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
IB/0018 
B.II.c.1.z - Change in the specification parameters 
26/07/2021 
n/a 
and/or limits of an excipient - Other variation 
IB/0017 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
26/07/2021 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
R/0015 
Renewal of the marketing authorisation. 
22/04/2021 
21/06/2021 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Bortezomib Sun in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
10/12/2020 
18/02/2021 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02004 
bortezomib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/424/202004. 
IB/0016 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
14/12/2020 
21/06/2021 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
N/0014 
Minor change in labelling or package leaflet not 
01/10/2020 
18/02/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/07/2020 
18/02/2021 
Annex II and 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
PL 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
01904 
bortezomib 
N/0011 
Minor change in labelling or package leaflet not 
30/08/2019 
18/02/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0010 
B.II.e.3.b - Change in test procedure for the 
31/07/2019 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
13/12/2018 
20/02/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01804 
bortezomib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/424/201804. 
N/0007 
Minor change in labelling or package leaflet not 
09/11/2018 
20/02/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0005 
Minor change in labelling or package leaflet not 
24/07/2018 
20/02/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/424/2
Periodic Safety Update EU Single assessment - 
30/11/2017 
n/a 
PRAC Recommendation - maintenance 
01704 
bortezomib 
IB/0004 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
07/09/2017 
15/11/2017 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/07/2017 
15/11/2017 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0001/G 
This was an application for a group of variations. 
24/11/2016 
15/11/2017 
SmPC, 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
Labelling and 
PL 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
